Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trialdoi:10.1007/s40200-024-01393-8EmpagliflozinSGLT2 inhibitor...
In the EMPA-HEART CardioLink-6 Randomized Clinical Trial, treatment with empagliflozin in patients with T2DM and coronary artery disease resulted in a significant reduction of left ventricular mass [31]. In contrast, we found a strong inverse correlation between insulin sensitivity indexes and left ...
Nikolaus Marx, Sebastian Reith, in Chronic Coronary Artery Disease, 2018 Empagliflozin SGLT-2-inhibitors are a new class of antidiabetic drugs that block the SGLT-2-receptor in the proximal tubule of the kidney, thus leading to increased urinary excretion of glucose along with sodium. The first...
Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post... S Ghanbari,S Gohari,T Reshadmanesh,... - 《Journal of Diabetes & Metabolic Disorders》 被引量: 0发表: 2024年 The heart failure bur...
Jardiance (empagliflozin tablet, film coated) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure; to reduce the risk of sustained decline in eGFR, end-stage kidney disease,...
[21]). We have demonstrated that MAO is present in the atrial tissue of patients with coronary artery disease with and without diabetes with the predominance of the MAO-B isoform, particularly in the former group [22]. We have also recently reported the contribution of MAO-related vascular ...
The clinical manifestations of DCM include left ventricular (LV) hypertrophy, myocardial fibrosis, and consequently impaired LV systolic and diastolic function, which eventually cause coronary artery disease, cardiac insufficiency, heart failure (HF), and sudden death [3]. Multiple mechanisms play direct...
min/1.73 m²; in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart TRIJARDY XR if renal function is stable [seeWARNINGS AND ...
The study design of the EMPA-HEART Cardiolink-6 has been previously described2 and was approved by the research ethics board of St. Michael’s Hospital. Briefly, patients with T2DM and stable coronary artery disease (CAD) were randomized to receive either empagliflozin (10 mg once daily; n =...
This condition contributes substantially to the morbidity and mortality associated with diabetes, primarily through myocardial dysfunction independent of coronary artery disease. Current treatment strategies focus on managing symptoms rather than targeting the underlying pathophysiological mechanisms, highlighting a ...